inappropriate ADH syndrome: A syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body.
Syndrome of inappropriate secretion of antidiuretic hormone
DOID EFO Endpoint Browser PheWeb
E4_ANTIDIU
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
232 |
4. Check minimum number of eventsNone |
232 |
5. Include endpointsNone |
232 |
6. Filter based on genotype QC (FinnGen only) |
199 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E22
- Name in latin
- Syndroma secretionis impropriae hormonis antidiuretici
Similar endpoints
↥List of similar endpoints to
Syndrome of inappropriate secretion of antidiuretic hormone
based on the number of shared cases.
Similar with more cases:
- Hyperfunction of pituitary gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1631 | 971 | 648 |
| Only index persons | 1405 | 854 | 551 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.56 | 74.37 | 67.48 |
| Only index persons | 72.04 | 74.92 | 67.57 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 199 | 108 | 91 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 70.18 | 71.25 | 68.91 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 205
- Matched controls
- 2050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E22.2
ICD-10 Finland
Syndrome of inappropriate secretion of antidiuretic hormone
4503599627370496.0
272.6
197
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
88.1
232.5
146
56
AA1AD
NOMESCO Finland
CT of head and brain
3.5
17.7
108
493
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.4
17.6
32
58
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
6.9
15.9
26
42
H02AB09
ATC
hydrocortisone; systemic
20.3
15.1
22
12
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
161.0
14.7
15
*
R11
ICD-10 Finland
Nausea and vomiting
4.0
11.3
36
104
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
46.0
11.1
13
*
N03AX14
ATC
levetiracetam; systemic
9.3
10.9
22
26
N03AG01
ATC
valproic acid; systemic, rectal
5.0
10.1
23
51
G40.9
ICD-10 Finland
Epilepsy, unspecified
5.3
10.0
21
43
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
10.0
59
251
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.7
9.9
70
327
S06.3
ICD-10 Finland
Focal brain injury
18.6
9.5
14
8
N30.0
ICD-10 Finland
Acute cystitis
3.0
9.3
49
195
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
12.3
9.2
16
14
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.9
9.1
53
222
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.9
8.9
49
199
N05BA04
ATC
oxazepam; oral
2.5
8.7
74
374
E87.8
ICD-10 Finland
Other disorders of electrolyte and fluid balance, not elsewhere classified
93.8
8.5
9
*
N06AX11
ATC
mirtazapine; oral
2.4
8.4
89
496
2536X
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Other disorders of neurohypophysis
+∞
8.4
8
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
8.4
8
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
8.1
8.4
18
24
M81.9
ICD-10 Finland
Osteoporosis, unspecified
4.4
8.3
22
55
R53
ICD-10 Finland
Malaise and fatigue
2.4
8.1
77
408
J01EA01
ATC
trimethoprim; systemic
2.4
7.7
73
385
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.3
7.5
91
532
D64.9
ICD-10 Finland
Anaemia, unspecified
2.9
7.3
39
155
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.4
7.2
15
19
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
31.2
7.2
9
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
9.3
7.2
14
16
N05CF01
ATC
zopiclone; oral
2.2
7.1
88
517
A06AD11
ATC
lactulose; oral
2.6
7.0
49
223
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.0
6.8
32
118
G41.9
ICD-10 Finland
Status epilepticus, unspecified
41.5
6.8
8
*
H02AA02
ATC
fludrocortisone; oral
12.8
6.7
11
9
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.0
6.5
19
51
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.3
6
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.0
6.3
29
106
N05BA01
ATC
diazepam; systemic, rectal
2.6
6.2
40
175
R42
ICD-10 Finland
Dizziness and giddiness
2.2
6.2
67
370
M05BX04
ATC
denosumab; parenteral
3.3
6.2
24
79
J01MA02
ATC
ciprofloxacin; systemic
2.1
6.1
97
620
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
70
22
47.80
112.74
2.5
1.2
261.12
266.06
mosm/kgh2o
0.25
60
17
130
171
19.05
106.53
3.5
1.9
413.24
396.42
nmol/l
0.33
117
156
34
14
28.78
25.35
1.4
1.3
25.09
25.43
ng/l
0.03
34
14
101
506
2.96
13.14
3.2
2.1
2.66
3.01
mg/l
1.00
86
434
152
954
3.29
13.08
11.2
6.9
1.20
1.21
mmol/l
1.02
128
819
21
37
6.21
11.74
3.6
2.6
4.69
5.04
kpa
1.68
21
37
38
116
3.79
11.05
9.8
7.9
24.36
24.64
mmol/l
0.16
38
116
108
606
2.65
10.70
2.9
2.2
751.20
223.71
u/l
0.45
103
572
68
312
2.76
9.95
3.1
2.3
2.39
2.25
g/l
1.25
63
288
125
777
2.56
9.68
3.9
2.8
141.06
130.60
ug/l
0.18
106
712
103
591
2.49
9.40
4.1
2.6
53.99
62.53
u/l
0.52
96
543
64
294
2.71
9.26
3.2
2.3
16.90
21.64
%
2.68
58
276
70
341
2.60
8.97
2.0
2.0
—
—
—
0
0
36
122
3.37
8.88
4.9
2.8
1.21
1.24
%
0.08
36
122
68
330
2.59
8.75
3.2
2.4
10.32
12.51
umol/l
1.84
62
306
147
1016
2.58
8.64
11.4
9.6
5.00
4.22
e9/l
2.45
130
881
35
119
3.34
8.58
4.9
2.7
0.63
0.62
%
0.10
35
119
131
872
2.39
8.17
12.2
6.1
1.20
1.21
mmol/l
0.81
122
798
129
861
2.34
7.88
5.5
4.7
33.66
35.19
g/l
2.38
119
798
56
261
2.58
7.73
2.0
1.9
—
—
—
0
0
55
257
2.56
7.53
8.8
6.7
1.31
1.16
mmol/l
0.09
43
207
24
69
3.81
7.53
2.1
5.9
27.92
93.05
mg/l
0.74
19
62
24
69
3.81
7.53
2.1
5.9
29.15
60.25
mg/l
1.07
19
62
31
107
3.24
7.39
4.9
3.8
2.27
1.66
mmol/l
0.42
24
80
68
370
2.25
6.53
2.2
1.7
1676.83
1233.68
nmol/l
1.62
40
271
118
800
2.12
6.41
6.4
4.3
56.28
83.31
ng/l
0.27
106
621
101
650
2.09
6.26
3.4
3.4
2.33
2.36
mmol/l
1.12
92
581
21
64
3.54
6.05
2.1
5.3
1.22
3.42
ratio
1.17
12
36
14
22
6.74
5.97
1.7
1.4
91.56
89.45
%
0.68
14
22
89
555
2.07
5.93
6.3
3.5
0.45
0.53
e6/l
0.13
77
403
115
796
2.01
5.65
3.5
2.4
82.51
79.91
nmol/l
0.43
100
699
49
249
2.27
5.44
2.0
2.0
—
—
—
0
0
136
1010
2.03
5.35
8.9
6.5
10.30
11.16
umol/l
0.46
128
952
14
29
5.10
4.91
5.3
1.8
9.15
7.09
pmol/l
0.26
14
29
42
210
2.26
4.81
7.0
3.5
—
—
—
0
0
103
726
1.84
4.43
7.8
4.5
0.00
0.02
estimate
0.50
38
156
98
684
1.83
4.32
3.6
3.4
1733.48
1568.81
ng/l
0.13
85
582
128
980
1.82
4.06
7.3
4.5
0.02
0.00
estimate
0.49
47
182
125
956
1.79
3.92
7.3
4.5
0.00
0.00
estimate
-0.00
48
197
126
966
1.79
3.92
7.3
4.5
0.00
8.12
estimate
0.50
48
200
82
556
1.79
3.88
7.7
4.4
0.00
0.01
estimate
0.50
42
173
135
1060
1.80
3.83
5.0
3.4
66.08
50.90
u/l
0.79
127
995
156
1281
1.91
3.82
7.2
4.3
16.02
15.03
pmol/l
3.89
145
1142
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
5
12.30
3.78
1.5
1.2
—
—
—
0
0
12
29
4.33
3.77
1.1
1.1
—
—
—
0
0
163
1362
1.96
3.73
12.5
8.3
85.33
79.53
u/l
0.75
155
1273
16
56
3.01
3.72
3.1
2.1
124.06
123.76
g/l
0.02
16
41
9
16
5.83
3.70
1.3
1.3
—
—
—
0
0
83
573
1.75
3.65
2.1
1.7
23.29
21.16
nmol/l
0.62
73
470
10
21
4.95
3.60
1.1
1.5
—
—
—
0
0
13
36
3.78
3.57
1.3
1.8
—
—
—
0
0
76
516
1.75
3.51
7.4
3.9
0.00
0.00
estimate
-0.00
40
150
13
37
3.68
3.47
4.2
3.0
1.17
1.20
mmol/l
1.53
13
37
13
37
3.68
3.47
4.2
3.0
4.27
4.06
mmol/l
1.50
13
37
13
37
3.68
3.47
4.2
3.0
96.00
105.51
mmol/l
2.45
13
37
7
10
7.20
3.39
1.1
1.0
—
—
—
0
0
30
151
2.16
3.36
7.5
5.6
24.80
24.25
mmol/l
0.35
25
143
6
7
8.78
3.28
1.5
1.0
—
—
—
0
0
40
227
1.95
3.26
4.3
5.7
250.41
249.05
u/l
0.02
34
213
11
29
3.95
3.24
1.4
3.3
32.82
31.97
pg
0.22
11
29
16
61
2.76
3.22
1.4
1.6
—
—
—
0
0
11
30
3.81
3.13
1.3
1.6
—
—
—
0
0
63
417
1.74
3.13
3.1
2.9
2.46
2.46
mmol/l
0.08
56
369
31
164
2.05
3.06
4.4
2.5
0.19
0.21
g/l
0.88
24
153
15
57
2.76
3.04
1.3
1.6
—
—
—
0
0
36
203
1.94
2.98
3.1
3.1
6.25
7.64
umol/l
0.36
28
169
153
1289
1.74
2.96
6.9
4.4
16.81
13.53
mm/h
1.57
147
1179
11
32
3.57
2.95
1.3
1.4
—
—
—
0
0
13
47
2.89
2.87
1.5
1.4
—
—
—
0
0
5
6
8.50
2.76
1.2
1.0
—
—
—
0
0
26
134
2.08
2.75
3.3
3.1
82.98
79.15
ng/l
0.07
18
115
7
14
5.13
2.75
1.3
1.0
—
—
—
0
0
7
14
5.13
2.75
1.3
1.0
—
—
—
0
0
12
40
3.12
2.74
1.3
1.1
—
—
—
0
0
112
882
1.59
2.74
2.8
2.8
—
—
—
0
0
13
49
2.76
2.68
1.5
1.3
—
—
—
0
0
57
382
1.68
2.67
2.3
1.9
467.76
54717448.18
pmol/l
0.74
45
318
9
25
3.72
2.60
1.4
1.3
—
160.14
—
0
10
17
75
2.38
2.59
3.2
2.9
—
—
—
0
0
5
7
7.28
2.56
6.8
6.4
—
—
—
0
0
6
12
5.11
2.42
1.0
1.1
—
—
—
0
0
12
47
2.65
2.31
1.3
1.4
—
—
—
0
0
27
152
1.89
2.25
2.2
1.6
—
—
—
0
0
20
103
2.04
2.14
1.6
1.4
—
—
—
0
0
15
69
2.27
2.10
1.5
1.2
—
—
—
0
0
50
345
1.59
2.05
5.1
3.2
0.85
1.06
e6/l
0.40
35
190
9
32
2.89
2.02
1.1
1.4
—
—
—
0
0
105
853
1.47
2.01
2.8
2.2
94.87
96.18
pmol/l
0.10
54
425
11
45
2.53
1.96
1.3
1.3
—
—
—
0
0
5
11
4.63
1.95
2.0
2.3
—
—
—
0
0
17
86
2.07
1.91
1.2
1.2
26.88
167.02
u/ml
—
5
28
11
46
2.47
1.88
1.2
1.3
—
—
—
0
0
101
824
1.44
1.84
3.6
2.8
—
—
estimate
—
0
0
5
12
4.24
1.83
1.2
1.2
—
—
—
0
0
7
23
3.11
1.81
1.9
1.2
—
—
—
0
0
20
111
1.89
1.76
15.4
8.9
15.42
15.38
%
0.02
20
105
24
142
1.78
1.74
4.1
3.3
57.31
59.66
ml/min/173m2
0.09
13
65
5
13
3.91
1.72
1.2
1.2
—
—
—
0
0
6
19
3.22
1.67
2.3
1.1
—
—
—
0
0
5
14
3.63
1.62
2.0
1.9
—
—
—
0
0
5
15
3.39
1.53
1.4
1.0
—
—
—
0
0
5
15
3.39
1.53
1.4
1.0
—
—
—
0
0
7
27
2.65
1.53
1.6
1.3
—
—
—
0
0
10
46
2.23
1.42
1.3
1.5
—
—
—
0
0
9
40
2.31
1.42
1.4
1.6
—
—
—
0
0
55
418
1.43
1.41
1.7
1.7
1.64
1.52
mg/l
0.11
46
337
11
53
2.14
1.41
1.4
1.5
—
—
—
0
0
44
321
1.47
1.40
5.5
3.3
0.88
2.49
e6/l
1.79
30
167
179
1666
1.59
1.39
37.0
18.3
25.55
25.81
mg/l
0.04
169
1406
6
23
2.66
1.37
1.5
2.0
—
—
—
0
0
61
477
1.40
1.33
2.6
3.2
306.07
352.68
umol/l
2.14
45
402
167
1537
1.47
1.32
8.5
5.4
1.92
2.01
mu/l
0.49
158
1386
51
389
1.41
1.28
1.4
1.3
3.47
1.14
u/ml
0.43
16
98
7
31
2.30
1.11
4.0
2.3
7.86
10.26
mmol/l
—
7
31
29
204
1.49
1.11
15.6
7.7
—
—
—
0
0
5
21
2.41
1.09
1.2
1.7
—
—
—
0
0
5
21
2.41
1.09
1.6
2.0
—
—
—
0
0
19
122
1.61
1.07
1.9
1.7
—
—
—
0
0
9
46
2.00
1.05
1.3
1.3
—
—
—
0
0
9
49
1.87
1.00
1.9
1.2
0.18
0.24
g/l
—
9
49
10
54
1.90
0.98
1.3
1.5
—
—
—
0
0
10
54
1.90
0.98
1.9
1.4
171.60
274.22
ug/g
—
5
30
75
634
1.29
0.95
4.4
3.9
8.01
8.38
mg/mmol
0.03
49
401
15
94
1.64
0.93
1.5
1.3
84.35
313.48
u/ml
0.76
15
85
8
43
1.89
0.88
1.9
1.5
—
—
—
0
0
8
43
1.89
0.88
1.9
1.5
—
—
—
0
0
10
60
1.70
0.73
1.2
1.9
—
—
—
0
0
53
443
1.26
0.72
3.8
2.3
—
—
—
0
0
40
487
0.78
0.70
3.5
4.8
20.63
21.58
%
0.15
23
250
29
224
1.34
0.70
3.7
4.0
7.55
38.68
ug/l
0.53
24
190
24
180
1.38
0.69
2.9
2.6
5.14
5.33
ug/l
0.05
18
160
152
1601
0.80
0.64
5.5
5.2
1.56
1.47
mmol/l
1.81
137
1451
28
349
0.77
0.59
2.4
3.2
0.65
0.76
ug/l
0.66
22
237
10
65
1.57
0.56
1.6
1.8
—
—
—
0
0
6
37
1.64
0.56
1.5
1.5
—
—
—
0
0
21
270
0.75
0.55
1.4
1.3
5.04
9.89
u/ml
—
5
97
7
49
1.44
0.46
1.3
1.6
3.24
6.42
mg/l
—
7
37
158
1641
0.84
0.45
6.3
6.2
2.36
2.59
mmol/l
2.86
144
1497
183
1779
1.27
0.43
52.7
27.3
4.12
4.41
e12/l
11.97
178
1733
19
152
1.28
0.38
2.6
2.6
247.39
224.40
ng/l
0.08
19
135
155
1606
0.86
0.38
5.4
5.4
4.24
4.53
mmol/l
2.79
140
1469
9
71
1.28
0.36
1.6
2.0
—
—
—
0
0
19
230
0.81
0.33
4.2
5.1
41.27
32.16
%
1.56
11
148
6
47
1.28
0.32
1.5
1.5
—
—
—
0
0
7
96
0.72
0.31
1.9
1.9
—
—
—
0
0
17
205
0.81
0.29
1.6
1.5
—
—
—
0
0
65
699
0.90
0.27
2.2
2.0
1.28
1.30
mmol/l
0.09
54
573
5
40
1.26
0.22
3.6
3.1
623.40
37.08
u/ml
—
5
40
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
5
43
1.17
0.21
1.2
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
13
149
0.86
0.14
1.4
1.4
—
—
—
0
0
46
437
1.07
0.11
7.3
4.7
1.01
1.02
kg/l
2.15
33
300
5
45
1.11
0.10
1.4
1.6
—
—
—
0
0
163
1610
1.06
0.09
6.1
5.6
6.11
6.08
mmol/l
0.09
145
1454
6
57
1.05
0.08
1.7
1.2
—
—
—
0
0
6
57
1.05
0.08
1.7
1.2
—
—
—
0
0
23
215
1.08
0.08
1.5
1.5
—
—
—
0
0
6
74
0.81
0.07
1.7
1.3
—
—
—
0
0
151
1526
0.96
0.06
4.4
4.5
1.13
1.28
mmol/l
2.43
135
1373
160
1586
1.04
0.05
8.2
7.1
40.92
40.16
mmol/mol
0.39
148
1473
30
291
1.04
0.02
1.4
1.3
19.08
29.35
iu/ml
0.95
13
94
160
1591
1.03
0.02
40.6
18.3
79.32
75.07
ml/min/173m2
1.64
151
1475
60
609
0.98
0.02
4.6
5.7
1.93
2.53
ug/l
0.68
53
539
8
84
0.95
-0.00
1.1
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
7.78
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
69.39
—
0
8
0
7
0.00
-0.00
0.0
1.4
—
8.40
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
8
87
0.92
-0.00
1.6
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
11.17
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint E4_ANTIDIU and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 2.117 [1.65, 2.72] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.177 |
During the follow-up period (1.1.1998 — 31.12.2019), 348 out of 767 females with E4_ANTIDIU died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 3.366 [2.32, 4.88] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 270 out of 507 males with E4_ANTIDIU died.
Mortality risk
Mortality risk for people of age
years, who have E4_ANTIDIU.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.198% | 0.597% |
| 5 | 1.064% | 3.778% |
| 10 | 2.882% | 8.794% |
| 15 | 5.999% | 16.438% |
| 20 | 10.228% | 26.295% |
Relationships between endpoints
↥Index endpoint: E4_ANTIDIU – Syndrome of inappropriate secretion of antidiuretic hormone
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data